• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,645
107
73
69
69

COUNTRY

68
21
17
11
10

CATEGORIES

  • 576
  • 122
  • 558
  • 80
  • 530
  • 43
  • 507
  • 17
  • 19
  • 25

PRICE

813
1,113
1,311
2,779

PUBLISHED

180
274
682
2,779

PRODUCT TYPE

2,204
495
68
7
2
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Analytical Tool - Lung Cancer Analytical Tool - Lung Cancer - Product Thumbnail Image

Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2014". According...

March 2014
Analytical Tool - Prostate Cancer Analytical Tool - Prostate Cancer - Product Thumbnail Image

Analytical Tool - Prostate Cancer

"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same...

March 2014
Analytical Tool - Cancer Therapeutic Antibodies Analytical Tool - Cancer Therapeutic Antibodies - Product Thumbnail Image

Analytical Tool - Cancer Therapeutic Antibodies

"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer....

March 2014
Analytical Tool - Peptides in Oncology Analytical Tool - Peptides in Oncology - Product Thumbnail Image

Analytical Tool - Peptides in Oncology

"Analytical Tool- Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is...

March 2014
Analytical Tool - Antibodies and Peptides in Oncology Analytical Tool - Antibodies and Peptides in Oncology - Product Thumbnail Image

Analytical Tool - Antibodies and Peptides in Oncology

"Analytical Tool – Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody...

March 2014
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling There are today 242 companies plus partners developing...

March 2014
RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014

Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses Non-self RNA appearing in a cell as a result of intracellular...

March 2014
Cytokine Therapy in Oncology Drug Pipeline Update 2014 Cytokine Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Cytokine Therapy in Oncology Drug Pipeline Update 2014

There are today 81 companies plus partners developing 106 cytokine drugs in 218 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs...

March 2014
Breast Cancer Drug Pipeline Update 2014 Breast Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Breast Cancer Drug Pipeline Update 2014

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic...

March 2014
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014 RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies. There are today...

March 2014
Lymphoma Drug Pipeline Update 2014 Lymphoma Drug Pipeline Update 2014 - Product Thumbnail Image

Lymphoma Drug Pipeline Update 2014

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 248 companies plus partners developing 372 lymphoma drugs in 588 developmental projects in cancer....

March 2014
Lung Cancer Drug Pipeline Update 2014 Lung Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Lung Cancer Drug Pipeline Update 2014

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D...

March 2014
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014 Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014

The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules. There are today 239 companies plus partners developing 366 Alpha6Beta4 integrin pathway...

March 2014
Ovarian Cancer Drug Pipeline Update 2014 Ovarian Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Update 2014

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for...

March 2014
Liver Cancer Drug Pipeline Update 2014 Liver Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Liver Cancer Drug Pipeline Update 2014

There are today 180 companies plus partners developing 214 drugs targeting liver cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last...

March 2014
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-3 signaling pathway activates the JAK/STAT, MAPK and PI 3-kinase signaling modules. There are today 181 companies plus partners developing 253 IL-3 pathway targeting drugs in 936 developmental...

March 2014
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 121 companies plus partners developing 162 IL-5 pathway targeting drugs in 642 developmental projects...

March 2014
Gene Therapy in Oncology Drug Pipeline Update 2014 Gene Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Gene Therapy in Oncology Drug Pipeline Update 2014

There are today 121 companies plus partners developing 109 gene therapy drugs in 278 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs...

March 2014
Angiogenesis in Oncology Drug Pipeline Update 2014 Angiogenesis in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Angiogenesis in Oncology Drug Pipeline Update 2014

There are today 283 companies plus partners developing 333 angiogenesis drugs in 1516 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased...

March 2014
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014

IL-7 signaling pathway mainly activates the JAK/STAT signaling module. There are today 64 companies plus partners developing 70 IL-7 pathway targeting drugs in 282 developmental projects in cancer....

March 2014
Loading Indicator

Our Clients

Our clients' logos